Search Results - "Rosada, Cecilia"

Refine Results
  1. 1

    Leptin deficiency in mice counteracts imiquimod (IMQ)‐induced psoriasis‐like skin inflammation while leptin stimulation induces inflammation in human keratinocytes by Stjernholm, Theresa, Ommen, Pernille, Langkilde, Ane, Johansen, Claus, Iversen, Lars, Rosada, Cecilia, Stenderup, Karin

    Published in Experimental dermatology (01-04-2017)
    “…Leptin is an adipocyte‐derived cytokine secreted mostly by adipose tissue. Serum leptin levels are elevated in obese individuals and correlate positively with…”
    Get full text
    Journal Article
  2. 2

    Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells by Kassem, Moustapha, Simonsen, Janne L, Rosada, Cecilia, Serakinci, Nedime, Justesen, Jeannette, Stenderup, Karin, Rattan, Suresh I.S, Jensen, Thomas G

    Published in Nature biotechnology (01-06-2002)
    “…Human bone marrow stromal cells (hMSCs) were stably transduced by a retroviral vector containing the gene for the catalytic subunit of human telomerase…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Interleukin-20 as a Target in Psoriasis Treatment by STENDERUP, KARIN, ROSADA, CECILIA, WORSAAE, ANNE, CLAUSEN, JES THORN, NORMAN DAM, TOMAS

    Published in Annals of the New York Academy of Sciences (01-09-2007)
    “…:  Interleukin‐20 (IL‐20) is a new member of the IL‐10 cytokine family discovered by a structural algorithm. IL‐20 transgenic mice displayed skin abnormalities…”
    Get full text
    Journal Article
  5. 5

    Exploring valrubicin’s effect on Propionibacterium acnes-induced skin inflammation in vitro and in vivo by Rottboell, Louise, De Foenss, Sarah, Thomsen, Kenneth, Christiansen, Helle, Andersen, Stine M., Dam, Thomas N., Rosada, Cecilia, Stenderup, Karin

    Published in Dermatology reports (17-12-2015)
    “…Acne is a common skin disease involving colonization with Propionibacterium acnes (P. acnes), hyperproliferation of the follicular epithelium and inflammatory…”
    Get full text
    Journal Article
  6. 6

    Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment by Raaby, Line, Rosada, Cecilia, Langkilde, Ane, Lauridsen, Kristina Lystlund, Vinter, Hanne, Ommen, Pernille, Kjellerup, Rasmus Boye, Johansen, Claus, Iversen, Lars

    Published in Experimental dermatology (01-09-2017)
    “…TNFα‐, IL‐23‐ and IL‐17‐targeting drugs are highly effective in the treatment of psoriasis. However, the precise molecular mechanism remains unknown. In…”
    Get full text
    Journal Article
  7. 7

    Activation and inhibition of the C-terminal kinase domain of p90 ribosomal S6 kinases by Fruergaard, Marlene Uglebjerg, Nielsen, Christine Juul Fælled, Kjeldsen, Cecilia Rosada, Iversen, Lars, Andersen, Jacob Lauwring, Nissen, Poul

    Published in Life science alliance (01-05-2023)
    “…The p90 ribosomal S6 kinases (RSKs) contain two distinct catalytic kinase domains, the N-terminal and C-terminal kinase domains (NTKD and CTKD, respectively)…”
    Get full text
    Journal Article
  8. 8

    Amelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model by Jakobsen, Maria, Stenderup, Karin, Rosada, Cecilia, Moldt, Brian, Kamp, Søren, Dam, Tomas N, Jensen, Thomas G, Mikkelsen, Jacob Giehm

    Published in Molecular therapy (01-10-2009)
    “…Tumor necrosis factor-α (TNF-α) is upregulated in psoriatic skin and represents a prominent target in psoriasis treatment. The level of TNF-α-encoding mRNA,…”
    Get full text
    Journal Article
  9. 9

    Langerhans cell markers CD 1a and CD 207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment by Raaby, Line, Rosada, Cecilia, Langkilde, Ane, Lauridsen, Kristina Lystlund, Vinter, Hanne, Ommen, Pernille, Kjellerup, Rasmus Boye, Johansen, Claus, Iversen, Lars

    Published in Experimental dermatology (01-09-2017)
    “…Abstract TNF α‐, IL ‐23‐ and IL ‐17‐targeting drugs are highly effective in the treatment of psoriasis. However, the precise molecular mechanism remains…”
    Get full text
    Journal Article
  10. 10

    Relationship between CD44 expression and cell proliferation in epithelium and stroma of colorectal neoplasms by Furuta, K, Zahurak, M, Yang, XL, Rosada, C, Goodman, SN, August, JT, Hamilton, SR

    Published in The American journal of pathology (01-10-1996)
    “…The cell surface glycoprotein CD44 is expressed primarily in the region of cell replication in the lower crypt epithelium of colorectal mucosa, and its…”
    Get full text
    Journal Article
  11. 11

    Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model by Stenderup, Karin, Rosada, Cecilia, Gavillet, Bruno, Vuagniaux, Grégoire, Dam, Tomas Norman

    Published in Acta dermato-venereologica (01-01-2014)
    “…Debio 0932 is a novel oral heat shock protein 90 (Hsp90) inhibitor developed for anti-cancer therapy. Surprising-ly, during the first clinical trial, one…”
    Get full text
    Journal Article
  12. 12

    Resolution of Psoriasis by a Leukocyte-Targeting Bacterial Protein in a Humanized Mouse Model by Stenderup, Karin, Rosada, Cecilia, Dam, Thomas N., Salerno, Erica, Belinka, Benjamin A., Kachlany, Scott C.

    Published in Journal of investigative dermatology (01-10-2011)
    “…Psoriasis is a very common chronic skin disease, affecting 2–3% of the world's population or more than 125 million individuals worldwide. The characteristic…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Valrubicin in a Topical Formulation Treats Psoriasis in a Xenograft Transplantation Model by Rosada, Cecilia, Stenderup, Karin, de Darkó, Elisabeth, Dagnaes-Hansen, Frederik, Kamp, Søren, Dam, Tomas Norman

    Published in Journal of investigative dermatology (01-02-2010)
    “…Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Valrubicin activates PKCa in keratinocytes: a conceivable mode of action in treating hyper-proliferative skin diseases by Laugesen, Ina Groenkjaer, Hauge, Eva, Andersen, Stine Maria, Stenderup, Karin, de Darkó, Elisabeth, Dam, Tomas Norman, Rosada, Cecilia

    Published in Journal of drugs in dermatology (01-10-2013)
    “…Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical…”
    Get more information
    Journal Article
  17. 17
  18. 18

    Topical application of valrubicin has a beneficial effect on developing skin tumors by Andersen, Stine M., Rosada, Cecilia, Dagnaes-Hansen, Frederik, Laugesen, Ina G., de Darkó, Elisabeth, Dam, Tomas N., Stenderup, Karin

    Published in Carcinogenesis (New York) (01-08-2010)
    “…Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact. In its…”
    Get full text
    Journal Article
  19. 19

    Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A by Stenderup, Karin, Rosada, Cecilia, Alifrangis, Lene, Andersen, Søren, Dam, Tomas Norman

    Published in Experimental dermatology (01-05-2011)
    “…:  Psoriasis xenograft transplantation models where human skin is transplanted onto immune‐deficient mice are generally accepted in psoriasis research. Over…”
    Get full text
    Journal Article
  20. 20